Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Live SK08 Powder (Bacteroides Fragilis) in Adult Patients with Active Mild to Moderate Ulcerative Colitis

NCT06725017 is registered in ClinicalTrials.gov with Guangzhou Zhiyi Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06725017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06725017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Live SK08 Powder (Bacteroides Fragilis) in Adult Patients with Active Mild to Moderate Ulcerative Colitis
Lead sponsor
Guangzhou Zhiyi Biotechnology Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 1, 2025
Completion date
August 1, 2027
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis (uc)